Pliant Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
The Cantor Global Healthcare Conference. I'm Pete Stavropoulos, biotech analyst at Cantor. With us, we have Pliant Therapeutics, a company I cover. And I'm pleased to introduce Bernard Coulie, President and CEO; and Ãric Lefebvre, CMO.
Welcome to the conference. Let's start off with a bit of an overview of Pliant, the company -- for those who are not familiar with the company.
Absolutely. And thanks, Pete, for having us here at the Cantor conference. Pliant Therapeutics started about seven years ago with a mission and a focus on developing novel therapeutics for fibrotic diseases. To that end, we have built a platform that is addressing integrins, which are known to activate TGF-β, which is the main driver of fibrosis. And by blocking those integrins, we basically block the TGF-β pathway, thereby blocking propagation -- initiation and propagation of fibrosis. So out of that platform, it's a small molecule library, basically unmatched in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
